Nothing Special   »   [go: up one dir, main page]

HRP20050743A2 - 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis - Google Patents

3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Info

Publication number
HRP20050743A2
HRP20050743A2 HR20050743A HRP20050743A HRP20050743A2 HR P20050743 A2 HRP20050743 A2 HR P20050743A2 HR 20050743 A HR20050743 A HR 20050743A HR P20050743 A HRP20050743 A HR P20050743A HR P20050743 A2 HRP20050743 A2 HR P20050743A2
Authority
HR
Croatia
Prior art keywords
acetic acid
methoxy
cyclohexylmethoxy
oxazol
arteriosclerosis
Prior art date
Application number
HR20050743A
Other languages
English (en)
Croatian (hr)
Inventor
Stapper Christian
Gretzke Dirk
Glombik Heiner
Falk Eugen
Goerlitzer Jochen
Keil Stefanie
Schaefer Hans-Ludwig
Wendler Wolfgang
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050743A2 publication Critical patent/HRP20050743A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HR20050743A 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis HRP20050743A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001579 WO2004076427A1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
HRP20050743A2 true HRP20050743A2 (en) 2006-08-31

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Family Applications After (2)

Application Number Title Priority Date Filing Date
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Country Status (34)

Country Link
US (5) US7365084B2 (ru)
EP (3) EP1599453B1 (ru)
JP (3) JP2006519199A (ru)
KR (3) KR20050105492A (ru)
CN (3) CN100439347C (ru)
AR (3) AR043433A1 (ru)
AT (3) ATE365159T1 (ru)
AU (3) AU2004215672B2 (ru)
BR (3) BRPI0407814A (ru)
CA (3) CA2517386A1 (ru)
CL (2) CL2004000391A1 (ru)
CO (2) CO5690580A2 (ru)
DE (4) DE10308355A1 (ru)
DK (3) DK1599453T3 (ru)
EC (2) ECSP055985A (ru)
ES (3) ES2287700T3 (ru)
HR (3) HRP20050743A2 (ru)
IL (2) IL170314A (ru)
MA (3) MA27736A1 (ru)
MX (3) MXPA05008995A (ru)
NO (3) NO20054396L (ru)
OA (2) OA13034A (ru)
PA (1) PA8596801A1 (ru)
PE (3) PE20040959A1 (ru)
PL (3) PL378437A1 (ru)
PT (3) PT1599455E (ru)
RS (1) RS20050594A (ru)
RU (3) RU2005130002A (ru)
SA (1) SA04250153A (ru)
TN (2) TNSN05204A1 (ru)
TW (3) TW200508210A (ru)
UY (2) UY28209A1 (ru)
WO (3) WO2004076428A1 (ru)
ZA (2) ZA200505765B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
WO2008018138A1 (fr) 2006-08-10 2008-02-14 Wood One Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
US8481778B2 (en) 2007-08-16 2013-07-09 Solvay (Societe Anonyme) Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
HUE027833T2 (en) 2008-02-29 2016-11-28 Nissan Chemical Ind Ltd Process for the preparation of a thiophene derivative and its intermediate
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184785A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
EP1108713A4 (en) * 1998-08-27 2006-04-05 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE COMPONENT
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
KR100693771B1 (ko) * 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
EP1196610A2 (en) 1999-07-09 2002-04-17 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
CN1365359A (zh) 1999-07-29 2002-08-21 伊莱利利公司 苯并呋喃哌嗪和苯并呋喃基高哌嗪:血清素激动剂
PT1218341E (pt) 1999-09-01 2005-11-30 Sanofi Aventis Deutschland Derivados de sulfonilcarboxamidas, processo para a sua preparacao e sua utilizacao como medicamentos
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PL357118A1 (en) 1999-12-03 2004-07-12 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
HU229042B1 (en) 2000-03-31 2013-07-29 Prosidion Ltd Method for the improvement of islet signaling in diabetes mellitus and for its prevention
IL152224A0 (en) 2000-04-25 2003-05-29 Kyorin Seiyaku Kk Stable crystals of thiazolidinedione derivative and process for the preparation thereof
AU2001252574B2 (en) 2000-04-28 2005-03-17 Asahi Kasei Pharma Corporation Novel bicyclic compounds
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
TR200401029T4 (tr) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
ATE361283T1 (de) * 2000-08-23 2007-05-15 Lilly Co Eli Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
PL362379A1 (en) 2000-12-21 2004-10-18 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
PL207798B1 (pl) * 2000-12-25 2011-02-28 Ono Pharmaceutical Co Pochodne dihydronaftalenu i zawierające je regulatory receptorów aktywowanych przez proliferatory peroksysomów, takie jak agonista PPAR, środek hipoglikemiczny i/lub hipolipidemiczny, środek do podwyższania poziomu cholesterolu HDL i/lub obniżania poziomu LDL i/lub VLDL oraz środki do zapobiegania i/lub leczenia chorób związanych z zaburzeniami metabolicznymi
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
KR20040030658A (ko) * 2001-06-07 2004-04-09 일라이 릴리 앤드 캄파니 페록시좀 증식제 활성화 수용체의 조절제
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
WO2003020269A1 (de) 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレーターとして用いるためのウレアリンカー誘導体
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
MA27737A1 (fr) 2006-02-01
DE502004004139D1 (de) 2007-08-02
PE20050293A1 (es) 2005-05-24
AU2004215673A1 (en) 2004-09-10
ECSP055986A (es) 2006-01-16
BRPI0407758A (pt) 2006-02-14
BRPI0407814A (pt) 2006-02-14
EP1599452A1 (de) 2005-11-30
US20050101637A1 (en) 2005-05-12
AU2004215677B2 (en) 2010-01-07
CO5690578A2 (es) 2006-10-31
PT1599453E (pt) 2009-07-14
CN1753879A (zh) 2006-03-29
ATE365159T1 (de) 2007-07-15
US7259177B2 (en) 2007-08-21
EP1599455B1 (de) 2009-07-01
CN1753881A (zh) 2006-03-29
ZA200505768B (en) 2005-11-23
SA04250153A (ar) 2005-12-03
ATE430738T1 (de) 2009-05-15
EP1599452B1 (de) 2007-06-20
PT1599452E (pt) 2007-09-12
MA27736A1 (fr) 2006-02-01
ES2329366T3 (es) 2009-11-25
CA2517381A1 (en) 2004-09-10
PL378437A1 (pl) 2006-04-03
OA13035A (en) 2006-11-10
DE502004009690D1 (de) 2009-08-13
WO2004076426A1 (de) 2004-09-10
MXPA05008988A (es) 2005-10-18
NO20054398D0 (no) 2005-09-22
IL170314A (en) 2010-11-30
EP1599455A1 (de) 2005-11-30
ES2326418T3 (es) 2009-10-09
ATE435217T1 (de) 2009-07-15
ECSP055985A (es) 2006-01-16
RU2005129995A (ru) 2006-01-27
CA2517386A1 (en) 2004-09-10
OA13034A (en) 2006-11-10
CN100398526C (zh) 2008-07-02
PL377735A1 (pl) 2006-02-20
US7365084B2 (en) 2008-04-29
CL2004000392A1 (es) 2005-04-22
AR043433A1 (es) 2005-07-27
HRP20050742A2 (en) 2006-09-30
UY28209A1 (es) 2004-09-30
JP2006519193A (ja) 2006-08-24
ZA200505765B (en) 2006-05-31
KR20050105492A (ko) 2005-11-04
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CL2004000391A1 (es) 2005-01-07
TNSN05204A1 (en) 2007-06-11
US20050215596A1 (en) 2005-09-29
PE20050292A1 (es) 2005-05-24
TNSN05206A1 (en) 2007-06-11
EP1599453B1 (de) 2009-05-06
TW200500349A (en) 2005-01-01
CN100439345C (zh) 2008-12-03
AU2004215672A1 (en) 2004-09-10
CN100439347C (zh) 2008-12-03
DE502004009453D1 (de) 2009-06-18
HRP20050744A2 (en) 2006-09-30
BRPI0407907A (pt) 2006-02-14
RS20050594A (en) 2007-12-31
NO20054408D0 (no) 2005-09-22
AR043427A1 (es) 2005-07-27
AU2004215673B2 (en) 2009-10-01
US7335671B2 (en) 2008-02-26
NO20054398L (no) 2005-11-02
PL378130A1 (pl) 2006-03-06
CA2516620A1 (en) 2004-09-10
JP2006519199A (ja) 2006-08-24
WO2004076428A1 (de) 2004-09-10
CO5690580A2 (es) 2006-10-31
PE20040959A1 (es) 2005-01-17
ES2287700T3 (es) 2007-12-16
TW200508210A (en) 2005-03-01
US7872034B2 (en) 2011-01-18
MXPA05008951A (es) 2005-11-04
US20080167354A1 (en) 2008-07-10
NO20054396L (no) 2005-11-11
RU2005129992A (ru) 2006-02-10
MA27742A1 (fr) 2006-02-01
CN1756748A (zh) 2006-04-05
AU2004215677A1 (en) 2004-09-10
KR20050106461A (ko) 2005-11-09
JP2006519194A (ja) 2006-08-24
RU2005130002A (ru) 2006-01-27
US20080015238A1 (en) 2008-01-17
DE10308355A1 (de) 2004-12-23
UY28210A1 (es) 2004-09-30
AU2004215672B2 (en) 2010-01-07
MXPA05008995A (es) 2005-10-18
EP1599453A1 (de) 2005-11-30
US20040209920A1 (en) 2004-10-21
NO20054396D0 (no) 2005-09-22
PT1599455E (pt) 2009-09-29
AR043432A1 (es) 2005-07-27
WO2004076427A1 (de) 2004-09-10
TW200510352A (en) 2005-03-16
DK1599453T3 (da) 2009-08-24
DK1599452T3 (da) 2007-10-01
KR20050106462A (ko) 2005-11-09
DK1599455T3 (da) 2009-11-09
IL170316A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
HRP20050743A2 (en) 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
ATE534650T1 (de) Neue cyanothiazolide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HRP20050710A2 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
MEP40908A (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
DE602004017174D1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
MEP60708A (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
HRP20050740A2 (en) Diarylcycloalkyl derivatives, method for their production and their use as medicaments
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
IL165220A0 (en) Novel compounds, their use and preparation
HRP20050715A2 (en) Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof
HRP20050741A2 (en) 1,3-substituted cycloalkyl containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
HRP20050737A2 (en) Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051229

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn